Last updated on September 2018

Biomarker for Creatine Deficiency Syndromes

Brief description of study

Development of a new MS-based biomarker for the early and sensitive diagnosis of creatine deficiency syndromes from plasma

Detailed Study Description

The creatine deficiency syndromes (CDS) are a group of inborn errors of metabolism which interrupt the biosynthesis or transportation of creatine. Individuals with creatine deficiency syndromes classically present with intellectual disabilities and seizure disorders and may present with pyramidal/extrapyramidal neurologic findings and behavioral problems as well.

There are three Cerebral Creatine Deficiency Syndromes:

  • Creatine Transporter Deficiency (CTD) - gene SLC6A8
  • Guanidinoacetate Methyltransferase Deficiency (GAMT) - gene GAMT
  • Arginine: Glycine Amidinotransferase Deficiency (AGAT) - gene GATM

X-linked Creatine Transporter Deficiency (CTD, SLC6A8 Deficiency, CRTR):

X-linked creatine transporter deficiency (CRTR-D) is a creatine deficiency syndrome (see this term) characterized clinically by global developmental delay / intellectual disability (DD/ID) with prominent speech/language delay, autistic behavior and seizures.

CRTR-D has been reported in more than 150 individuals worldwide. The onset of symptoms occurs during infancy, usually before the age of 2 years. Males are mainly affected, but females can also have various combinations and severities of disease manifestations. CRTR-D is consistently characterized by mild to severe intellectual deficit, and expressive speech and language delay. Behavioral disorders (mainly autism and hyperactivity) are present in all affected individuals. Affected individuals often experience seizures and may present low weight gain, muscular hypotonia, and poor muscle mass. Subtle dysmorphic features such as midface hypoplasia, long face, and prominent chin have been reported in various affected male patients. Epilepsy and extrapyramidal symptoms may also occur occasionally. In adult patients, cardiac and gastrointestinal disorders have been reported. Carrier females are typically asymptomatic, but learning disabilities have been described in some. CRTR-D is not a life threatening disease, however live expectancy is limited, particularly in those who have severe seizures and associated physical disabilities.

Guanidinoacetate Methyltransferase Deficiency (GAMT)

Mutations in the GAMT gene are a relatively rare cause of creatine deficiency syndrome. Affected individuals may demonstrate cerebral creatine deficiency on MR spectroscopy and high GAA in urine. Guanidinoacetate methyltransferase deficiency is inherited in an autosomal recessive manner and is caused by biallelic mutations in the GAMT gene. This gene maps to 19p13.3 and is involved in the biosynthesis of creatine. Individuals with GAMT deficiency typically present with severe intellectual disabilities and seizure disorders which may be resistant to drug therapy. Behavioral problems, including autistic behaviors and self-mutilation are common, and pyramidal/extrapyramidal symptoms affect about one-half of patients with GAMT deficiency. Dietary management of GAMT deficiency via manipulation of critical amino acids may improve clinical outcome.

Arginine: Glycine Amidinotransferase (AGAT):

L-Arginine:glycine amidinotransferase (AGAT) deficiency is a very rare type of creatine deficiency syndrome characterized by global developmental delay, intellectual disability, and myopathy. AGAT deficiency is characterized by global developmental delay, appearing in infancy, which can be associated with language impairment and autistic behavior in some, as well as a mild to moderate intellectual disability. Progressive muscle weakness and fatigability have been reported in older patients. Seizures and failure to thrive have also been described. If creatine supplementation is administered early enough, psychomotor delay may be avoided. AGAT deficiency is caused by mutations in the L-arginine:glycine amidinotransferase gene (GATM) located to chromosome 15q15.1. This gene encodes AGAT, which converts arginine and glycine to ornithine and guanidino-acetate in the creatine cycle pathway. AGAT deficiency is transmitted in an autosomal recessive manner and genetic counseling is possible.

New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood (plasma) of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.

Therefore it is the goal of the study to identify and validate a new biochemical marker from the plasma of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.

Clinical Study Identifier: NCT02934854

Contact Investigators or Research Sites near you

Start Over

Arndt Rolfs, Prof.

Albrecht-Kossel-Institute for Neuroregeneration (AKos) Centre for Mental Health Disease University of Rostock
Rostock, Germany

Anil Jalan, MD

NIRMAN, University of Mumbai
Mumbai, India

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.